Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vasopressin antagonists.

R Lemmens-Gruber1, M Kamyar

  • 1Department of Pharmacology and Toxicology, University of Vienna, 1090 Vienna, Austria. rosa.lemmens@univie.ac.at

Cellular and Molecular Life Sciences : CMLS
|June 24, 2006
PubMed
Summary

Vasopressin antagonists, known as vaptans, target V1a and V2 receptors. These drugs show promise for treating various cardiovascular, renal, and psychiatric disorders, with conivaptan approved for euvolemic hyponatremia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities.

Biochemical pharmacology·2013
Same author

Effects of beauvericin to mammalian tissue and its production by Austrian isolates ofFusarium proliferatum and Fusarium subglutinans.

Mycotoxin research·2013
Same author

Voltage-gated sodium channels: mutations, channelopathies and targets.

Current medicinal chemistry·2010
Same author

Clinical pharmacy services and solid organ transplantation: a literature review.

Pharmacy world & science : PWS·2009
Same author

Effects of the anthelmintic drug PF1022A on mammalian tissue and cells.

Biochemical pharmacology·2009

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Vasopressin, acting through V1a and V2 receptors, significantly influences water balance and cardiovascular function.
  • Dysregulation of vasopressin is implicated in numerous conditions, including heart failure, hyponatremia, hypertension, and renal diseases.

Purpose of the Study:

  • To review the therapeutic potential of vasopressin receptor antagonists (vaptans).
  • To explore the applications of selective and non-selective vaptans in various medical conditions.

Main Methods:

  • Literature review of vasopressin receptor antagonist pharmacology and clinical applications.
  • Analysis of existing data on vaptans, including selective (V1a or V2) and non-selective agents.

Main Results:

  • Vasopressin antagonists demonstrate efficacy in water-retaining and cardiovascular diseases.
  • Vaptans show potential for treating cerebral ischemia, stroke, Raynaud's disease, dysmenorrhea, and psychiatric disorders.
  • Conivaptan, a non-selective V1a/V2 antagonist, is FDA-approved for euvolemic hyponatremia.

Conclusions:

  • Vasopressin antagonists represent a significant therapeutic class with broad applications.
  • Targeting vasopressin receptors offers a promising strategy for managing diverse pathologies.
  • Further research into selective V1b antagonists may yield novel treatments for psychiatric conditions.

Related Experiment Videos